Regeneron Pharmaceuticals (REGN) Upgraded to Sell at BidaskClub

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.

REGN has been the subject of several other reports. JPMorgan Chase & Co. raised their price objective on shares of Regeneron Pharmaceuticals from $455.00 to $457.00 and gave the stock a “neutral” rating in a report on Wednesday. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Jefferies Group restated a “hold” rating and issued a $500.00 price objective (up from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Piper Jaffray Companies restated an “overweight” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, September 29th. Finally, Evercore ISI lowered their price objective on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a report on Thursday, November 16th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $471.19.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $17.48 on Friday, reaching $374.36. 1,426,670 shares of the company’s stock traded hands, compared to its average volume of 681,361. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals has a twelve month low of $340.96 and a twelve month high of $543.55. The stock has a market capitalization of $38,430.00, a price-to-earnings ratio of 34.00, a PEG ratio of 1.50 and a beta of 1.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same period last year, the business posted $3.13 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% compared to the same quarter last year. analysts anticipate that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Schaper Benz & Wise Investment Counsel Inc. WI increased its position in shares of Regeneron Pharmaceuticals by 27.4% during the fourth quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 12,998 shares of the biopharmaceutical company’s stock valued at $4,887,000 after acquiring an additional 2,794 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $1,417,000. Hudson Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $287,000. Hennessy Advisors Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $756,000. Finally, Steward Partners Investment Advisory LLC increased its position in shares of Regeneron Pharmaceuticals by 495.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 307 shares in the last quarter. 66.82% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/27/regeneron-pharmaceuticals-regn-upgraded-to-sell-at-bidaskclub.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply